Drawing for SERVING OVERLOOKED PATIENTS

USPTO serial 97388326

SERVING OVERLOOKED PATIENTS

Reviewed by CopyMark Law Group

Reg. 8187953Status 700Registered
Filing date
Status date
Registration date
Mar 24, 2026
Examiner
NKOJO, RHODA K
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with SERVING OVERLOOKED PATIENTS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Douglas R. Wolf

Douglas R. Wolf WOLF, GREENFIELD & SACKS, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations sold as a kit for use by pharmacists and physicians in creating compounded hormone replacement medicines, topical anti-inflammatory and ultrasound gels, pain and gastrointestinal disorders treatment medicines, and anti-inflammatory, antimicrobial, and antifungal treatment medicines; medicines for the treatment of cardiovascular diseases and disorders, colitis, muscle spasm, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; antibiotics; pharmaceutical products for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders having vancomycin, enalapril, lisinopril, and methotrexate as the active pharmaceutical ingredient; antacids; muscle relaxants; hormone replacement medicines; topical anti-inflammatory and ultrasound gels; pharmaceutical preparation for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; pharmaceuticals for use in the treatment of cancer and autoimmune diseases and disorders, and for the treatment and prevention of renal, oncological, inflammatory, gastrointestinal, gastroesophageal, and cardio-vascular diseases and disordersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 24, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Mar 24, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 28, 2026SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Feb 28, 2026CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Feb 17, 2026SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jul 22, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 21, 2025EX4GSOU EXTENSION 4 GRANTED—
Jul 21, 2025AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 4, 2025IUAFUSE AMENDMENT FILED—
Apr 4, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 3, 2025EXT4SOU EXTENSION 4 FILED—
Feb 19, 2025EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Oct 16, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 16, 2024EX3GSOU EXTENSION 3 GRANTED—
Oct 16, 2024EXT3SOU EXTENSION 3 FILED—
Oct 16, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 22, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 21, 2024EX2GSOU EXTENSION 2 GRANTED—
Feb 21, 2024EXT2SOU EXTENSION 2 FILED—
Feb 21, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 10, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 6, 2023EX1GSOU EXTENSION 1 GRANTED—
Oct 6, 2023EXT1SOU EXTENSION 1 FILED—
Oct 6, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 18, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 21, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 21, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 1, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 18, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 10, 2023DOCKASSIGNED TO EXAMINER—
May 4, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 3, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance